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Summary: Human atrial natriuretic peptide and arginine vasopressin were coextracted from EDTA-plasma
with Sep-Pak C18 cartridges, and the hormones were coeluted from the cartridges by a solution containing
900 ml/l of methanol, 5 ml/l of trifluoroacetic acid and 95 ml/l of water. After volume reduction under
nitrogen the eluates were lyophilized, dissolved in buffer and aliquots were used for radioimmunological
detennination of both hormones. Both procedures used delayed addition of [125I]-labelled tracer to enhance
sensitivity. Recoveries were 95 + 2% for human atrial natriuretic peptide and 96 ± 3% vor arginine vasopres-
sin (mean ± SD). Minimal detectable doses were 2 pg/tube of human atrial natriuretic peptide and 0.5 pg/
tube of arginine vasopressin (B0 — 3 SD). Intra-assay variabilities were ± 8% for both tests. Simultaneous
extraction of both honnones with high recovery was achieved, thus increasing sensitivity and specificity, at
the same tirüe reducing sample volume requirements and technician time.
Radioimmunologische Bestimmung von Arginin- Vasopressin und humanem atrialen natriuretischen Peptid nach
gemeinsamer Extraktion aus Plasma
Zusammenfassung: Humanes atriales natriuretisches Peptid und Arginin-Vasopressin wurden mittels Sep-Pak
C18 Säulen aus EDTA-Plasmä gemeinsam extrahiert, mit einer Lösung, bestehend aus 900 ml/l Methanol,
5 ml/l Trifluoressigsäure und 95 ml/l Wasser coeluiert und nach Volumenreduktion im Stickstoffstrom
lyophilisiert. In Püffer gelöste Aliquote des Lyophilisats wurden zur radioimmunologischen Bestimmung
beider Hormone verwendet. Bei beiden Prozeduren wurde zur Erhöhung der Sensitivität der [125I]-markierte
Tracer verzögert zugegeben. Die Wiederfindung betrug 95 ± 2% für humanes atriales natriuretisches Peptid
und 96 + 3% für Arginin-Vasopressin (Mittelwert ± Standardabweichung). Die Nachweisgrenze war bei
2 pg/Röhrchen für humanes atriales natriuretisches Peptid und bei 0,5 pg/Röhrchen für Arginin-Vasopressin
(B0 — 3 Standardabweichungen), in beiden Fällen ergab sich eine Intraassay-Variabilität von ±8%. Die
Vorteile der Methode sind die gleichzeitige Extraktion der beiden Hormone, die hohe Wiederfindung und
damit erhöhte Sensitivität und Spezifität sowie die Verringerung des nötigen Probenvolumens und des
Laboraufwandes.
Introduction which, after processing (9) are released into the circu-
Specific granules of mammalian cardial atriocytes (l, lation (10-18) and are important mediators of renal
2) contain structurally closely related peptides (3 - 9), and cardiovascular homoeostasis.
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In humans the so called alpha-form of human atrial
natriuretic peptide is released into circulating blood
(14, 16, 19). -Human atrial natriuretic peptide con-
sists of 28 aminoacids: NH-Ser-Leu-Arg-Arg-Ser-Ser-
CysS-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-
Gln-Ser-Gly-Leu-Gly-CysS-Asn-Ser-Phe-Arg-Tyr-
COOH. The intrachain disulphide bridge is essential
for biological activity. -Human atrial natriuretic
peptide is cleaved off from the carboxy-terminus of
its precursor -human atrial natriuretic peptide, 126
amino acids in length. ß-Human atrial natriuretic
peptide, whose biological role is quite unclear, most
probably is an antiparallel dimer of -human atrial
natriuretic peptide (7, 8; 9).
Human atrial natriuretic peptide induces natriuresis/
diuresis, relaxes smooth muscle and suppresses aldo-
sterone production in the adrenal cortex ((25 — 30);
see 1. c. (9, 20—23) for recent reviews). Close regula-
tory associa^ion with the renin-angiotensin-aldo-
sterone System has been reported (23, 24, 29, 30).
Furthermore human atrial natriuretic peptide prob-
ably antagonizes arginine vasopressin-excretion (31,
32). Elucidation of physiological functions of human
atrial natriuretic peptide therefore implicates meas-
urements of plasma levels of the whole set of these
hormones.
In this paper we present a method for simultaneous
extraction by Sep-Pak C 18 cartridges of human atrial
natriuretic peptide äs well äs arginine vasopressin
from the same blood plasma sample. Aliquots of
purified and concentrated plasma extracts are used
for human atrial natriuretic peptide and arginine va-
sopressin RIA. A significant simplification together
with high recovery, high sensitivity and increased
specificity are the advantages of the method.
Materials and Methode
Blood sampling
Blood samples were collected into EDTA-coated plastic-tubes
(Greiner, Vienna, Austria) kept on ice. Centrifugation gave
EDTA-plasma which was frozen quickly with liquid nitrogen
and stored at -70 °C until used (although we did not find any
significant decay of human atrial natriuretic peptide if the
samples were stored at —25 °C for l month).
Extraction of the hormones from EDTA-plasma sam-
ples
Sep-Pak C 18 cartridges (Waters/Millipore) were adapted to
the lid of a manifold extraction apparatus built according to our
mstructions (Fa. Augmüller, Vienna, Austria). A 5 ml plastic
synnge without plunger was then stuck onto each cartridge, to
serve äs sample/eluent recipient. Liquid placed into the syringes
could be forced to flow through the cartridges by applying a
moderate negative pressure (vacuum-pump). The cartridges
were first prewashed with 4ml of methanol. Additionaliy three
sequential pretreatment steps were performed with 4ml each
of Solutions containing methanol/trifluoroacetic acid/water in
the following volume amounts per liter: 50 ml/10 ml/940 ml,
100 ml/5 ml/895 ml, and 900 ml/5 ml/95 ml. Finally, prior to
adsorption of sample, they were reequilibrated with the solution
used in the first step of the pretreatment cycle. Both hormones
were coextracted from EDTA-plasma^amples (usually 5 ml) by
loading the samples onto the Sep Pak-syringe combination,
followed by vacuunr-aided slow passage of the samples through
the cartridge (about l min duration). Non-adsorbed material
was washed away by 4 ml of the solution used in the second
step of pretreatment. Both hormones were finally eluted simul-
taneoüsly by 4 ml (2 2 ml) of the above solution used for
the third pretreatment step. After volume reduction to about
0.5 ml by a nitrogen stream at 37 °C, samples were lyophilized
and stored at — 25 °C until assayed. The lyophilized samples
were dissolved in l ml RIA buffer and aliqupts were used for
honnone assay. Sep-Pak cartridges could be used at least three
times without any detectable differences in results, when iderU>
ical samples were applied.
Human atrial natriuretic peptide RIA components
Rabbit anti-a-humän atrial natriuretic peptide äs well äs syn-
thetic -human atrial natriuretic peptide were purchased from
NOVAbiochem AG (Läufelfingen, Switzerland). [12$I]ipdoty-
rosyl-28-a-human atrial natriuretic peptide was obtained from
Amersham International (Amersham, UK). Immunoprecipitat-
ing reagent (sheep ariti-rabbit/polyethyleneglycol complex)
from SORIN Biomedica (Saluggia, Italy) was used äs second
antibody. For human atrial natriuretic peptide RIA Standards,
radiolabelled -human atrial natriuretic peptide and antibody
to -human atrial natriuretic peptide were dissolved in RIA
buffer consisting of: 0.05 mol/1 sodium phosphate, pH = 8.1,
l mmol/1 EDTA, 3 g/l bovine serum albumin (RIA grade, frac-
tion V, Sigma, St. Louis, USA), l ml/l Triton X 100 (Serva
Feinbiochemikalien, Heidelberg, FRG), 0.1 g/l sodium azide.
Antibody from one vial was dissolved in 24 rnl RIA buffer
and kept on ice until used (freezing destroys antibody). Serial
dilutions of synthetic -human atrial natriuretic peptide in RIA
buffer were used to construct the Standard curve. Aliquots of
lyophilized EDTA-plasrna extracts dissolved in RIA buffer were
used äs samples of unknown human atrial natriuretic peptide
content.
Arginine vasopressin components
The components of the arginine vasopressin RIA kit were from
either Immuno Nuclear Corporation (Stillwater, Minnesota) or
Bühlmann Laboratories AG (Basel, Switzerland), except for
the sample büffers and seeond antibodies.
Performance of the assays
Aliquots of the lyophilized extracts dissolved in human atrial
natriuretic peptide RIA buffer were used for assay of both
hormones. Both radioimmimoassays were done äs assays with
delayed addition of tracer and incubation at 4 °C. Incubation
conditions for arginine vasopressin RIA were modified and
adapted to those used for RIA of human atrial natriuretic
peptide: sample or Standard (human atrial nätriuretic peptide:
0.1 ml; arginine vasopressin: 0.2 ml) were added to 0.1 ml of
antibody solution. After 24 hours incubation, 0.1 ml of the
respective [125I]-labelled tracer was added and incubation con-
tinued for a further 24 h ([125I]a-human atrial natriuretic peptide
approx. 20000 counts/min; [125i]arginine vasopressin 6000 to
15000 counts/min). Bound antigen was separated from un-
bound by incubation with second antibody-immunoprecipitat-
ing reagent for 30 min at room temperature, followed by
addition of l ml RIA buffer and centrifugätion at 4000g for
20 min at 4 °C. Supernatants were removed by aspiration, and
the radioactivity in the pellet was.^etermined in a gamma-
counter. Data evaluation was computer-aided, using a linear
logit/log fit.
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For example, cross-reactivity with atriopeptin l, atriopeptin II and
atriopeptin III is less than 1%.
o Convenienf Separation
Utilizes Amersham's Amerlex-M* magnetic Separation System.
Conventional centrifugation can be used if preferred.
o High sertsitiviiy, wide ränge
% B/B0
2 4 8 16 32 64
fmol ANP/tube
o Flexible
Alternative protocol allows results to be obtained in 24 hours with
little loss of sensitivity.
o Adaptable
High cross reactivity (70%) with rat oANP allows assays to be
carried out in this species.
*Amerlex is a trademark of Amersham International plc.
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Results
Characteristics of adsorption and e lut ion of
the hormones from Sep-Pak C18 cartridges
Adsorption and elution were evaluated by spiking
EDTA plasma samples with either [125I]a-human
atrial natriuretic peptide or [125I]arginine vasopressin,
followed by adsorption onto Sep-Pak C 18 cartridges
s described above, and step-wise elution with diluted
trifluoroacetic acid (5 ml/l) containing increasing am-
ounts of methanol. The adsorption/desorption-condi-
tions for human atrial natriuretic peptide and argi-
nine vasopressin determined in these experiments are
shown in figure l. As the peptides cannot be separ-
ated satisfactorily from each other because of over-
lapping peaks, we chose elution with 900 ml/l meth-
anol in 5 ml/l of trifluoroacetic acid to desorb both
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Fig. 1. Elution proflle of
a) [125I]4abelled arginine vasppressin and
b) α-human atrial natriuretic peptide adsorbed onto
Sep-Pak C 18 cartridges.
To 5 ml ΕΡΤΑ-plasma, either [125I]arginine vasopres-
sin (148000 counts/min) or [12SI]a-human atrial na-
triuretic peptide (530 000 counts/min) were added.
After adsorption onto separate Sep-Pak cartridges
s described in the text, the hormones were eluted
by a stepwise gradient (4 ml/fraction) of methanol
in diluted trifluoroacetic acid (5 ml/l).
Recovery
Aliquots of EDTA-plasma were spiked with synthetic
hormone preparations simultaneously in a series of
concentration steps according to table l. After extrac-
tion of the hormones s described above, they were
determined by specific RIA. The amounts found were
compared with those calculated, and the results are
summarized in table l a for human atrial natriuretic
peptide and in table l b for arginine vasopressin.
Typical Standard curves are shown in figure 2.



















































































In the assay procedure originally developed in our
laboratory for determination of human atrial natriur-
etic peptide (33) the peptide was eluted from the Sep-
Pak cartridge after an additional washing step with
methanol/trifluoroacetic acid/water (400 ml/5 ml/595
ml) which would elute part of arginine vasopressin.
Control experiments did not reveal any significant
difference in human atrial natriuretic peptide re-
covery when human atrial natriuretic peptide was
eluted s described above.
Discussion
It is about one year since the discovery of human
atrial natriuretic peptide and the first reports of its
determination in human plasma by several groups
(10—19). Blood sampling conditions and procedures
for concentrating human atrial natriuretic peptide
J.'Clin. Cheim. Oih. Biochem. / Vol. 24,1986 / No. 8
562 Hartter and Woloszczuk: Determination of arginine vasopressin and human atrial natriuretic peptide
Fig. 2a Fig. 2b
0.5 1 2 U 8 16
Arginine vasopressin [pg/assay t übe]
3.12 6.25 125 25 50. 100 200
Human atrial natriuretic peptide [pg/assay tube]
Fig. 2. RIA-calibration curves for arginine vasopressin (a) and human atrial natriuretic peptide (b) B0 = [125I]-labelled tracer
bound at zero dose, B = [125I]-labelled tracer bound at dose shown on the abscissa; B0 and B values are corrected for
non-specific binding (NSB). Results shown are mean ± SD of triplicates.
Fig. 2 a: NSB = 3.5%, B0 = 44%; maximal coefficient of Variation in the useful ränge (between B/B0 = 85% and B/B0
= 15%) was ± 8%; minimal detectable amount of peptide (B0 — 3 SD) was 0.5pg/tube.
Fig. 2b: NSB = 4.2%, B0 = 32%; maximal coefficient of Variation in the useful ränge (between B/B0 = 85% and B/B0
= 15%) was ± 8%; minimal detectable amount of peptide (B0 — 3 SD) was 2pg/tube.
had to be elaborated and antibodies with sufficient
affinity and specificity had to be raised. In our hands
human atrial natriuretic peptide proved to be stable
in ice-cooled EDTA-plasma for at least 2 hours (re-
covery of added [125I]-labelled -human atrial natriur-
etic peptide not lower than 95%, recovery of authen-
tic endogenous human atrial natriuretic peptide 92%
without any significant change when compared to
samples processed immediately).
There is some controversy concerning normal levels
of human atrial natriuretic peptide. This might be
due to assay-dependent variations in human atrial
natriuretic peptide-recoveries, insufficient sensitivity
of the assay, plasma interference with direct assays,
Variation in the salt/water Status of the „normal per-
sons" due to lack of control of water balance, the
possibility of circadian variations in human atrial
natriuretic peptide-levels, orthostasis-dependent vari-
ations (16) not taken into account at blood sampling,
etc.
To circumvent recovery problems due to proteolytic
degradation or intrinsic sample variables, we chose
extraction-enrichment and purification of the hör-
mones prior to determination. Interfering sample
constituents were thereby eliminated and a higher
accuracy of the assay at low concentrations was achi-
eved. At this point our somewhat sophisticated precyc-
ling procedure of the Sep-Pak catridges should be
substantiated: When screening for variabilities in re-
coveries we suspected that during the adsorption-
elution procedure small particles of column material
might bleed out from the Sep-Pak column. Such
particles, if eluted together with the peptides, could
bind part of these when the lyophilised extracts were
dissolved, thereby rendering considerable amounts of
peptides undetectable by RIA. Although we did not
test this possibility in detail, observation of the eluate
showed that it soinetimes contained granulär mate-
rial. Recoveries were better and results more repro-
ducible when we pretreated the cartridges identicälly
to the adsorption-wäshing-desorption procedure for
the peptides.
In our opinion, the increased laböratory effort is
largely compensated by coextraction of böth hor-
mones and by the high accuracies and recoveries
achieved in comparison with other methods. This
assay procedure therefore might be useful to those
interested in investigation of the physiological role of
human atrial natriuretic peptide and its regulatory
association with the other systfems of salt and water
homoeostasis in man.
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